Loading
Supernus Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Khattar Jack A., was filed 27 Aug 2019.
Insider Decl.
546
Thresholds
n/a
Buy Volume
€171,425
1 ops. · all time
Sell Volume
€86M
156 ops. · all time
Who traded when
BuySaleJack A. Khattar22 sales
Padmanabh P. Bhatt12 sales
Charles W. Newhall III6 sales
Frank Mottola6 sales
Georges Gemayel4 sales
Bethany Sensenig3 sales
+4 other insiders
Since the insiders bought
- -15.8%Entry US$26.77 · Close at T+365 US$22.54
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Supernus Pharmaceuticals, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$60.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,666 of 26,248 companies
37.3
score / 100
Value26
Quality49
FCF yld1.9%
Earn yld-1.6%
EV/EBITDA57.4x
ROE-10%
Gross mgn90%
Net mgn-5.4%
Debt/EBITDA1.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$41.21
Analyst consensus
4 analystsStrong buy
US$55.00Target US$60.50(+47%)US$67.00
Income statement
RevenueUS$719M
Gross profitUS$644.4M90% margin
EBITDAUS$42.5M6% margin
Net income-US$38.6M-13.2% margin
Valuation
PER (forward)9.6x
P/Book2.3x
Beta0.55
Balance sheet & cash
Market capUS$2.4B
Total debtUS$41M
Free Cash FlowUS$46M
Debt / Equity4%
Profitability & ownership
ROE-10.5%
ROA0.4%
% insiders4.3%
% institutions106.0%
Last declaration on 14 August 2026
Declarations546 total
2,500 shares0Common StockSEC:0001539215-26-000012:0
1,250 shares0Common StockSEC:0001194020-26-000015:0
29,849 shares0Common StockSEC:0001539937-26-000012:0
1,650 shares0Common StockSEC:0001804567-26-000014:0
750 shares0Common StockSEC:0001836067-26-000010:0
1,158 shares@ US$46.570.0021% mcap1.7% of flowCommon StockSEC:0001539215-26-000012:1
604 shares@ US$46.570.0011% mcap5.0% of flowCommon StockSEC:0001194020-26-000015:1
12,642 shares@ US$46.570.023% mcap4.9% of flowCommon StockSEC:0001539937-26-000012:1
363 shares@ US$46.570.0007% mcap60.0% of flowCommon StockSEC:0001836067-26-000010:1
797 shares@ US$46.570.0015% mcap3.8% of flowCommon StockSEC:0001804567-26-000014:1
4,250 shares@ US$29.610.4% of flowCommon StockSEC:0001539215-26-000008:1
18,000 shares@ US$32.202.1% of flowCommon StockSEC:0001539215-26-000008:2
5,000 shares@ US$27.940.5% of flowCommon StockSEC:0001539215-26-000008:3
34,114 shares@ US$50.186.1% of flowCommon StockSEC:0001539215-26-000008:4
15,886 shares@ US$50.492.9% of flowCommon StockSEC:0001539215-26-000008:5
22,750 shares@ US$39.403.2% of flowCommon StockSEC:0001539215-26-000008:6
12,250 shares@ US$36.751.6% of flowCommon StockSEC:0001539215-26-000008:7
15,000 shares@ US$38.602.0% of flowCommon StockSEC:0001539215-26-000008:8
27,710 shares@ US$49.954.9% of flowCommon StockSEC:0001539215-26-000008:9
22,290 shares@ US$50.734.0% of flowCommon StockSEC:0001539215-26-000008:10
7,250 shares@ US$39.401.0% of flowCommon StockSEC:0001539215-26-000008:11
6,838 shares@ US$49.551.2% of flowCommon StockSEC:0001539215-26-000008:12
412 shares@ US$50.480.1% of flowCommon StockSEC:0001539215-26-000008:13
22,750 shares@ US$36.750.026% mcap26.1% of flowCommon StockSEC:0001539215-26-000008:0
12,500 sharesCommon StockSEC:0001539937-26-000008:1
25 of 546 declarations
About Supernus Pharmaceuticals, Inc.
A single purchase appears among the 546 insider filings of Supernus Pharmaceuticals, Inc., a US healthcare company valued at USD 2.32 billion: Jack A. Khattar's (President, CEO), EUR 171,425 on August 23, 2019, which is 1% of open-market trades. Against it, 156 sales total EUR 86,212,622, with a median of EUR 308,696.
Jack A. Khattar is also behind the two largest sales: EUR 4,271,844 on November 7, 2024 and EUR 4,202,110 the next day; Stefan K.F. Schwabe (Executive Vice President R&D) sold EUR 3,679,464 on September 7, 2017. Jack A. Khattar signs 149 filings, 41 of them sales. Padmanabh P. Bhatt (Sr. VP of IP, CSO) has 112, 45 of them sales, Frank Mottola (SVP, Chief Tech. Ops. Officer) 51, Timothy C. Dec (Senior Vice-President & CFO) 37 and Gregory S. Patrick (Sr. VP Chief Financial Officer) 33.
Read moreShow less
On top come 188 option exercises, 163 grants and 38 other filings. Annual volume rises to 115 in 2025 and 91 in 2026. Over the last twelve months, 98 filings were published, of which 20 sales and no purchase.
